The cancer fight has too many one-hit wonders. Big trials, splashy headlines, and then the quiet fade-out when the science can’t keep the beat. But every so often, a co. steps in with a track that doesn’t just play, it sticks. OncoC4, Inc., out of Rockville, MD, isn’t chasing the hype cycle. They’re building an album, and every track is designed to hit the system hard. Founded in 2020 by immunologists Dr. Yang Liu and Dr. Pan Zheng, the duo that already sold OncoImmune to Merck for $425M, this isn’t a comeback tour. It’s the next era.
This week, OncoC4 closed a $50M Series B led by GBA Fund, with repeat plays from HM Capital, 3E Bioventures Capital, and Kaitai Capital. Even the founders themselves doubled down. When the people who know the science best are writing checks, you know the conviction isn’t for show. Layer in the $200M upfront from BioNTech in 2023 to license gotistobart, with another $1B on the table in milestones and royalties, and you’ve got more than capital, you’ve got a co-sign from one of biotech’s heavyweight producers. Total funding now tops $250M, and it’s not just fuel. It’s validation.
The lead single? Gotistobart (BNT316/ONC-392), a next-gen anti-CTLA-4 antibody engineered to stay active instead of getting chewed up in lysosomal purgatory. It’s in a Phase 3 global trial for squamous NSCLC, with 160 sites already live. That’s not theoretical science, that’s a pipeline moving. Then there’s AI-081, a bispecific marrying anti-PD-1 and anti-VEGF in a head-to-tail format. Early Phase 1/2 data showed an objective response at just 1 mg/kg. Translation: even at the lowest dose, the drug’s got teeth. And don’t sleep on ONC-841, their Siglec-10 antagonist. First-in-class, already dosing pts, and showing potential not just in cancer but in neurodegeneration, including Alzheimers. If you’re counting, that’s 3 high-value shots on goal, each built on differentiated science.
The leadership bench reads like a who’s who of biotech operators. Dr. Yang Liu as CEO and CSO, stacking 200+ peer-reviewed pubs. Dr. Pan Zheng as CMO, blending clinical precision with translational vision. Add Helen F. Schiltz as COO, Shiniu Wei as CFO, and a supporting cast of vets like James DeYonker in legal, Pan Pan in BD, and Dr. Jamie Chen in clinical ops. Their advisory circle pulls in legends like Dr. Lieping Chen and Dr. Michael Caligiuri. This isn’t a rookie band, it’s a supergroup.
The lesson? Momentum in biotech doesn’t come from checks alone; it comes from conviction at every layer, science, partnerships, execution. OncoC4 shows how you take a post-acquisition spinout, lace it with proprietary platforms, and lock arms with partners who amplify reach. The $50M Series B isn’t a finish line. It’s an accelerant, a signal that global oncology isn’t waiting for incremental change, it’s demanding new weapons.
OncoC4 isn’t promising to change the world with press releases. They’re doing it with antibodies, bispecifics, and pipelines built to outlast the noise. Cancer doesn’t play fair. Fortunately, neither does this team.
